[1]沈旭峰.COPD患者下呼吸道感染的病原菌分布及耐药性分析[J].医学信息,2021,34(19):146-148.[doi:10.3969/j.issn.1006-1959.2021.19.039]
　SHEN Xu-feng.Analysis of Pathogen Distribution and Drug Resistance of Lower Respiratory Tract Infection in Chronic Obstructive Pulmonary Disease Patients[J].Medical Information,2021,34(19):146-148.[doi:10.3969/j.issn.1006-1959.2021.19.039]
点击复制

COPD患者下呼吸道感染的病原菌分布及耐药性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年19期
页码:
146-148
栏目:
调查分析
出版日期:
2021-10-01

文章信息/Info

Title:
Analysis of Pathogen Distribution and Drug Resistance of Lower Respiratory Tract Infection in Chronic Obstructive Pulmonary Disease Patients
文章编号:
1006-1959（2021）19-0146-03
作者:
沈旭峰
如东县中医院检验科，江苏 如东 226400
Author(s):
SHEN Xu-feng
Department of Laboratory,Rudong Hospital of Traditional Chinese Medicine,Rudong 226400,Jiangsu,China
关键词:
慢性阻塞性肺疾病; 下呼吸道感染; 病原菌; 耐药性
Keywords:
Chronic obstructive pulmonary disease; Lower respiratory tract infection; Pathogen; Drug resistance
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2021.19.039
文献标志码:
A
摘要:
目的 分析慢性阻塞性肺疾病（COPD）患者下呼吸道病原菌分布特点与耐药性。方法 选择2018年1月-2020年6月我院收治的253例COPD合并下呼吸道感染患者为研究对象，对其痰液样本进行病原菌分离、培养、检查及药敏试验，分析其病原菌分布及耐药性。结果 253例COPD合并下呼吸道感染患者共计培养分离病原菌268株，其中革兰氏阴性菌株共194株，占比72.39%，主要包括肺炎克雷伯菌、大肠埃希菌、铜绿假单胞菌、鲍曼不动杆菌；革兰氏阳性菌株共51株，占比19.03%，主要包括金黄色葡萄球菌、肺炎链球菌；真菌23株，占比8.58%，主要包括白色念珠菌、其他念珠菌。革兰氏阴性菌对头孢菌素耐药性较强，对左氧氟沙星、美罗培南、帕拉西林他唑巴坦耐药性较弱；革兰氏阳性菌对青霉素耐药性强，对万古霉素、利奈唑胺耐药性弱；真菌对两性霉素B耐药性弱。结论 COPD合并下呼吸道感染患者主要病原菌为革兰氏阴性菌，不同病原菌对抗菌药物耐药性不同，应结合药敏结果合理选择抗菌药物治疗，以提高治疗效果，促进患者康复。
Abstract:
Objective To analyze the distribution characteristics and drug resistance of pathogenic bacteria in lower respiratory tract of patients with chronic obstructive pulmonary disease(COPD).Methods A total of 253 patients with COPD complicated with lower respiratory tract infection in our hospital from January 2018 to June 2020 were selected for observation and analysis. The sputum samples were isolated, cultured and examined for pathogenic bacteria. At the same time, the drug sensitivity test was conducted with commonly used antibiotics to summarize and sort out the distribution and drug resistance of pathogenic bacteria.Results A total of 268 strains of pathogenic bacteria were isolated from 253 COPD patients with lower respiratory tract infection, including 194 gram-negative strains, accounting for 72.39%, mainly including Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii; 51 gram-positive strains, accounting for 19.03%, mainly including Staphylococcus aureus, Streptococcus pneumoniae; 23 strains of fungi, accounting for 8.58%, mainly including Candida albicans, other Candida. Among them, gram-negative bacteria were generally resistant to cephalosporins, but weak to levofloxacin, meropenem and palacillin tazobactam; gram positive bacteria were strongly resistant to penicillin, but weak to vancomycin and linezolid; fungi were weak in resistance to amphotericin B.Conclusion The main pathogenic bacteria in patients with copd complicated by lower respiratory tract infection are gram-negative bacteria, and different pathogenic bacteria have different antimicrobial resistance. Antimicrobial therapy should be selected reasonably based on drug sensitivity results, so as to improve the therapeutic effect and promote the rehabilitation of patients.

参考文献/References:

[1]张蕾,杨青,赵钊,等.慢性阻塞性肺疾病合并侵袭性肺曲霉病的临床特征及危险因素分析[J].中华临床感染病杂志,2020,13(2):113-118.[2]宋孝鹏.COPD机械通气患者下呼吸道感染病原菌和耐药性分析[J].深圳中西医结合杂志,2019,29(17):108-109.[3]孙超.慢性阻塞性肺疾病急性加重期下呼吸道感染的病原学特点和耐药性分析[J].临床合理用药杂志,2020,13(23):107-108.[4]肖琴锋.COPD患者下呼吸道感染的病原菌分布及耐药性分析[J].浙江临床医学,2018,20(1):148-150.[5]张会娟,李建英.COPD合并社区获得性下呼吸道感染病原菌和耐药性分析[J].民航医学,2016,26(3):103-105.[6]李一鹏.慢性阻塞性肺疾病患者下呼吸道感染铜绿假单胞菌耐药性分析的临床意义研究[J].中国现代药物应用,2019,13(2):14-15.[7]徐雪梅,吴思颖,谢轶,等.慢性阻塞性肺疾病合并下呼吸道感染患者病原菌分布与耐药性分析[J].成都医学院学报,2017,12(2):175-181.[8]李国庆,胡静,黄勇.老年COPD合并气胸患者下呼吸道感染病原菌特点及药敏分析[J].现代医药卫生,2017,33(8):1127-1130.[9]聂国忠,郭嘉琪.药敏试验在慢性阻塞性肺疾病合并下呼吸道感染中的应用及临床意义[J].检验医学与临床,2018,15(9):1347-1349.[10]肖纯荣.慢性阻塞性肺疾病合并下呼吸道感染患者细菌学检测及其耐药性分析[J].临床合理用药杂志,2017,10(18):81-83.[11]刘晓立,高维.老年慢性阻塞性肺病急性加重期患者呼吸道致病菌分布及耐药性分析[J].临床肺科杂志,2016,21(10):1865-1868.[12]甄继军,贺兴萍.重度慢性阻塞性肺疾病患者下呼吸道多药耐药菌感染的临床特点[J].中国实用医刊,2016,43(22):105-107.[13]胡俊芳,罗敏,王挺.慢性阻塞性肺疾病下呼吸道感染病原学分析及抗生素选择[J].西部医学,2016,28(1):74-76,83.[14]段友红,张梦兰,夏新红,等.92例COPD急性加重期患者痰液病原菌分布及耐药情况分析[J].实验与检验医学,2020,38(1):123-125.[15]习静,脱鸣富,魏育芳,等.不同病程COPD并发下呼吸道感染病原菌分离及耐药情况分析[J].中国抗生素杂志,2020,45(8):798-803.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(19):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(19):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,31(19):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(19):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,31(19):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(19):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,31(19):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(19):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
　ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(19):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]

更新日期/Last Update: 1900-01-01